{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:56:09Z","timestamp":1760298969591,"version":"3.40.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T00:00:00Z","timestamp":1405987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00228-014-1719-5","type":"journal-article","created":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T05:39:58Z","timestamp":1405921198000},"page":"1203-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy"],"prefix":"10.1007","volume":"70","author":[{"given":"Yoshiaki","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,22]]},"reference":[{"key":"1719_CR1","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","volume":"32","author":"C Giraud","year":"2004","unstructured":"Giraud C, Tran A, Rey E, Vincent J, Tr\u00e9luyer JM et al (2004) In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: Importance of CYP2C19. Drug Metab Dispos 32:1279\u20131286","journal-title":"Drug Metab Dispos"},{"key":"1719_CR2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0090-9556(25)08020-1","volume":"11","author":"RH Levy","year":"1983","unstructured":"Levy RH, Lane EA, Guyot M, Brachet-Liermain A, Cenraud B et al (1983) Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man. Drug Metab Dispos 11:286\u2013292","journal-title":"Drug Metab Dispos"},{"key":"1719_CR3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0773.1990.tb00799.x","volume":"67","author":"H Bun","year":"1990","unstructured":"Bun H, Monjanel-Mouterde S, Noel F, Durand A, Cano JP (1990) Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam. Pharmacol Toxicol 67:136\u2013140","journal-title":"Pharmacol Toxicol"},{"key":"1719_CR4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/088307389701200311","volume":"12","author":"JG Theis","year":"1997","unstructured":"Theis JG, Koren G, Daneman R, Sherwin AL, Menzano E et al (1997) Interactions of clobazam with conventional antiepileptics in children. J Child Neurol 12:208\u2013213","journal-title":"J Child Neurol"},{"key":"1719_CR5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00007691-199208000-00002","volume":"14","author":"S Sennoune","year":"1992","unstructured":"Sennoune S, Mesdjian E, Bonneton J, Genton P, Dravet C et al (1992) Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit 14:269\u2013274","journal-title":"Ther Drug Monit"},{"key":"1719_CR6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.braindev.2004.02.010","volume":"26","author":"K Kosaki","year":"2004","unstructured":"Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y et al (2004) A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev 26:530\u2013534","journal-title":"Brain Dev"},{"key":"1719_CR7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/FTD.0000000000000015","volume":"36","author":"J Saruwatari","year":"2014","unstructured":"Saruwatari J, Ogusu N, Shimomasuda M, Nakashima H, Seo T et al (2014) Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in Japanese patients with epilepsy. Ther Drug Monit 36:302\u2013309","journal-title":"Ther Drug Monit"},{"key":"1719_CR8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","volume":"8","author":"SI Johannessen","year":"2010","unstructured":"Johannessen SI, Landmark CJ (2010) Antiepileptic drug interactions\u2014Principles and clinical implications. Curr Neuropharmacol 8:254\u2013267","journal-title":"Curr Neuropharmacol"},{"key":"1719_CR9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/00007691-199912000-00004","volume":"21","author":"M Contin","year":"1999","unstructured":"Contin M, Riva R, Albani F, Baruzzi AA (1999) Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit 21:604\u2013608","journal-title":"Ther Drug Monit"},{"key":"1719_CR10","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, Rey E, D\u2019Athis P et al (2000) Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 356:1638\u20131642","journal-title":"Lancet"},{"key":"1719_CR11","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.105.007237","volume":"34","author":"C Giraud","year":"2006","unstructured":"Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J et al (2006) In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 34:608\u2013611","journal-title":"Drug Metab Dispos"},{"key":"1719_CR12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/FTD.0b013e318283b49a","volume":"35","author":"Y Yamamoto","year":"2013","unstructured":"Yamamoto Y, Takahashi Y, Imai K, Miyakawa K, Nishimura S et al (2013) Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N desmethyl-clobazam concentrations in patients with epilepsy. Ther Drug Monit 35:305\u2013312","journal-title":"Ther Drug Monit"},{"key":"1719_CR13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA et al (2008) Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia 49:1239\u20131276","journal-title":"Epilepsia"},{"key":"1719_CR14","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","volume":"77","author":"YT Ng","year":"2011","unstructured":"Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA (2011) Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 77:1473\u20131481","journal-title":"Neurology"},{"key":"1719_CR15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","volume":"35","author":"J Leon de","year":"2013","unstructured":"de Leon J, Spina E, Diaz FJ (2013) Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit 35:30\u201347","journal-title":"Ther Drug Monit"},{"key":"1719_CR16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007691-200206000-00007","volume":"24","author":"TW May","year":"2002","unstructured":"May TW, Rambeck B, J\u00fcrgens U (2002) Serum concentrations of topiramate in patients with epilepsy: Influence of dose, age, and comedication. Ther Drug Monit 24:366\u2013374","journal-title":"Ther Drug Monit"},{"key":"1719_CR17","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1248\/bpb.26.1734","volume":"26","author":"N Fukuoka","year":"2003","unstructured":"Fukuoka N, Tsukamoto T, Uno J, Kimura M, Morita S (2003) Influence of coadministered antiepileptic drugs on serum zonisamide concentrations in epileptic patients: Quantitative analysis based on suitable transforming factor. Biol Pharm Bull 26:1734\u20131738","journal-title":"Biol Pharm Bull"},{"key":"1719_CR18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1248\/bpb.35.487","volume":"35","author":"Y Yamamoto","year":"2012","unstructured":"Yamamoto Y, Inoue Y, Matsuda K, Takahashi Y, Kagawa Y (2012) Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients. Biol Pharm Bull 35:487\u2013493","journal-title":"Biol Pharm Bull"},{"key":"1719_CR19","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","volume":"35","author":"L Cerveny","year":"2007","unstructured":"Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F et al (2007) Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 35:1032\u20131041","journal-title":"Drug Metab Dispos"},{"key":"1719_CR20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jcph.13","volume":"53","author":"F Salem","year":"2013","unstructured":"Salem F, Rostami-Hodjegan A, Johnson TN (2013) Do children have the same vulnerability to metabolic drug\u2013drug interactions as adults? A critical analysis of the literature. J Clin Pharmacol 53:559\u2013566","journal-title":"J Clin Pharmacol"},{"key":"1719_CR21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","volume":"32","author":"M Walzer","year":"2012","unstructured":"Walzer M, Bekersky I, Blum RA, Tolbert D (2012) Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy 32:340\u2013353","journal-title":"Pharmacotherapy"},{"key":"1719_CR22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF00542148","volume":"26","author":"HR Ochs","year":"1984","unstructured":"Ochs HR, Greenblatt DJ, L\u00fcttkenhorst M, Verburg-Ochs B (1984) Single and multiple dose kinetics of clobazam and clinical effects during multiple dosage. Eur J Clin Pharmacol 26:499\u2013503","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1719-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-014-1719-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1719-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T21:51:25Z","timestamp":1746309085000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-014-1719-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,22]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["1719"],"URL":"https:\/\/doi.org\/10.1007\/s00228-014-1719-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2014,7,22]]}}}